Compare iShares MSCI India ETF (INDA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI India ETF trades at $48.82, while Merck & Co., Inc. trades at $125.46 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while iShares MSCI India ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| INDA | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $129.52 |
52-Week Low | $45.42 | $77.60 |
Market Cap | — | $307.25B |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $48.56, down 0.72% on the day, with neutral technical signals overall. The ETF shows bullish moving averages but neutral oscillators, with key support and resistance clustered around $49. Recent news highlights India's strong 7.8% GDP growth (CNBC, 2026-06-05) and ongoing comparisons with other India-focused ETFs amid foreign investor outflows.
The outlook remains mixed: India's robust economic expansion and strategic sector composition offer growth potential, but risks include geopolitical tensions, AI investment underperformance, and regulatory changes in clean energy. Analyst sentiment is cautiously optimistic, with some seeing value in INDA's discount to S&P 500 valuations.
Merck (MRK) trades at $125.25, down 1.76% on the day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 results surpassing expectations. Fundamentals show robust profitability with a 73.91% gross margin and 13.59% net margin, though valuations are elevated with a P/E of 35.04. Recent news highlights the company's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook is supported by a strong analyst consensus with a $137.30 price target and 68% buy ratings, but risks include high valuation multiples, competitive pressures in oncology, and significant capital expenditure for pipeline development as indicated by negative investing cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
